Patent intelligence · US
US 7566718
Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
Patent details — US 7566718
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 28, 2009
- Expiration
- Jul 23, 2029
- Applicant
- Pharmacopeia Drug Discovery, Inc.
- Claims
- 41
- CPC classes
- A61P, A61P1/04, A61P17/00, A61P17/06
Quick answer
US 7566718 (Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity) is held by Pharmacopeia Drug Discovery, Inc.. Status: granted. Granted Jul 28, 2009. Expires Jul 23, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Pharmacopeia Drug Discovery, Inc.
- Grant date
- Expiration
- Claims
- 41
- CPC classes
- A61P, A61P1/04, A61P17/00, A61P17/06, A61P25/00, A61P27/02
More from Pharmacopeia Drug Discovery, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12427173
Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
granted -
US 12428415
Matriptase 2 inhibitors and uses thereof
granted -
US 12421236
Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
granted -
US 12420085
Synergistic therapies for inter vertebral disc degeneration
granted -
US 12421231
Azaindole derivatives and their use as ERK kinase inhibitors
granted -
US 12403069
Adapter for use in a planetary mixer
granted -
US 12398179
Nanomolar peptides and derivatives to differentially modulate ephrin receptors
granted -
US 12396924
Adapter for use in a planetary mixer
granted
Frequently asked questions
What is US patent 7566718?
US 7566718 (Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity) is held by Pharmacopeia Drug Discovery, Inc.. Status: granted. Granted Jul 28, 2009. Expires Jul 23, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7566718?
Pharmacopeia Drug Discovery, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 706 pharmaceutical patents for this assignee.
When does US 7566718 expire?
Our index shows an expiration date of Jul 23, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.